This application requests Cancer Center Support Grant funding for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa. This is the second CCSG competitive renewal for the HCCC. The HCCC functions administratively as a matrix Cancer Center with 189 Center members from six colleges and 36 departments across the University. It leverages the resources and expertise provided by the medical center and across the University to support and strengthen transdisciplinary cancer research. The HCCC has extensive support from both the institution and via private support. The members of the HCCC have $74.2 million in total annual cancer-related, peer-reviewed, external research support. Of this, over $20.4 million comes from the NCI. The HCCC is organized into six research programs that are each designed to be translational in nature. Together they encompass a broad spectrum of strength in basic laboratory, clinical and population research. These programs are 1) Cancer Immunology &Immunotherapy, 2) Cancer Signaling and Experimental Therapeutics, 3) Free Radical Cancer Biology, 4) Tumor Imaging, 5).Cancer Epidemiology, and 6) Cancer Genomics and Cell Growth. In addition to the Administrative Core, the HCCC supports eleven shared resources including: 1) DNA, 2) Gene Transfer Vector, 3) Radiation and Free Radical Research, 4) Flow Cytometry, 5) Central Microscopy Research Facility, 6) Small Animal Imaging, 7) Tissue Procurement 8) Bioinformatics, 9) Population Research, 10) Biostatistics, and 11) Clinical Trials Support. Through these programs and cores, and an effective organizational structure, the HCCC enhances interactions, supports collaborations, and sets the direction of future cancer research activities at the HCCC.

Public Health Relevance

The Cancer Center Support Grant supports the infrastructure of the Holden Comprehensive Cancer Center. This infrastructure allows the Center to foster excellence in research across a broad spectrum of scientific areas relevant to cancer, and translate those advances to the clinic with the goal of reducing the morbidity and mortality of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-14
Application #
8640082
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2000-07-14
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
14
Fiscal Year
2014
Total Cost
$2,126,551
Indirect Cost
$718,483
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Meyerholz, David K; Ofori-Amanfo, Georgina K; Leidinger, Mariah R et al. (2017) Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem 65:607-618
Ebbert, Jon O; Little, Melissa A; Klesges, Robert C et al. (2017) Step Care treatment for smoking cessation. Health Educ Res 32:1-11
Sfeir, J G; Drake, M T; LaPlant, B R et al. (2017) Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 7:e526
Mohiuddin, I; Allen, B G (2017) A Single-Institution Experience in Treating Thymic Carcinoma. Int J Radiat Oncol Biol Phys 98:229
Miller, Benjamin J (2017) CORR Insights®: Is It Appropriate to Treat Sarcoma Metastases With Intramedullary Nailing? Clin Orthop Relat Res 475:218-220
Huang, Jianguo; Chen, Mark; Whitley, Melodi Javid et al. (2017) Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun 8:15999
Jethava, Yogesh S; Barlogie, Bart; Tricot, Guido J (2017) Drug Combinations with Transplantation for Myeloma. N Engl J Med 377:91-2
Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E (2017) Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions. Biol Res Nurs 19:481-490
Rogers, Laura M; Mott, Sarah L; Smith, Brian J et al. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res 23:954-961
Eppsteiner, Robert W; Fowlkes, Jonathan W; Anderson, Carryn M et al. (2017) Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment. Ann Otol Rhinol Laryngol 126:525-529

Showing the most recent 10 out of 831 publications